Claims for Patent: 6,492,422

Summary for Patent: 6,492,422

Title:	Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
Abstract:	Tricyclic sulfonamide compounds and derivatives are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as inhibitors of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 and for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysm, heart failure, left ventricular dilation, restenosis, periodontal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative disorders including stroke, head trauma, spinal cord injury, Alzheimer\'s disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson\'s disease, Huntington\'s disease, prion diseases, myasthenia gravis, and Duchenne\'s muscular dystrophy.
Inventor(s):	O\'Brien; Patrick Michael (Stockbridge, MI), Picard; Joseph Armand (Canton, MI), Sliskovic; Drago Robert (Saline, MI)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	10/108,817
Patent Claims:	1. A compound of Formula I ##STR39## wherein n is zero or an integer of 1 or 2; X is ##STR40## R is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, trifluoromethyl, alkanoyloxyalkyl, alkanoylaminoalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, N-alkylpiperazinoalkyl, N-phenylalkylpiperazinoalkyl, morpholinoalkyl, thiomorpholinoalkyl, piperidinoalkyl, pyrrolidinoalkyl, N-alkylalkylpiperidinoalkyl, pyridylalkyl, thienylalkyl, quinolinylalkyl, thiazolylalkyl, cycloalkyl, cycloalkylalkyl, phenyl, phenyl substituted by one to three substituents selected from the group consisting of: hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, alkylamino, dialkylamino, halogen, cyano, nitro, trifluoromethyl and on adjacent carbon atoms by either a one to two carbon alkenylenedioxy group or a two to three carbon alkenyleneoxy group, phenylalkyl, phenylalkyl wherein phenyl is substituted by alkyl, alkoxy, halogen, or trifluoromethyl, heteroaryl, heteroaryl substituted by one to two substituents selected from the group consisting of: alkyl, and halogen, biphenyl, biphenyl, substituted by alkyl, alkoxy, halogen, trifluoromethyl, or cyano, biphenylalkyl or biphenylalkyl wherein biphenyl is substituted by alkoxy, halogen, trifluoromethyl, or cyano; D is zero or an integer of 1 to 3; L is zero or an integer of 1 to 3; R.sup.1 is hydrogen a side chain or a natural amino acid or a side chain of an unnatural amino acid; Y is OR.sup.3 wherein R.sup.3 is hydrogen, methyl, ethyl, or benzyl, or NH--OR.sup.4 wherein R.sup.4 is hydrogen, alkyl, or benzyl; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 which is ##STR41## 3. The compound according to claim 2 wherein n is zero or an integer of 1; and X is --CH.sub.2 --. 4. The compound according to claim 3 wherein n is zero or an integer of 1; X is --CH.sub.2 --; and R is hydrogen. 5. The compound according to claim 4 wherein n is zero or an integer of 1; X is --CH.sub.2 --; R is hydrogen; and Y is OH. 6. The compound according to claim 5 wherein n is zero or an integer of 1; X is --CH.sub.2 --; R is hydrogen; and Y is NHOH. 7. A compound selected from the group consisting of: (S) 2-(2,3-Dihydro-1H-8-oxa-cyclopenta[a]indene-6-sulfonylamino)-3-methyl-buty ric acid; (S) 3-Methyl-2-(6,7,8,9-tetrahydro-5H-10oxa-benzo[a]azulene-2-sulfonylamino)-b utyric acid; (S) 2-(2,3-Dihydro-1H-8-oxa-cyclopenta[a]indene-6-sulfonylamino)-N-hydroxy-3-m ethyl-butyramide; (S) N-Hydroxy-3-methyl-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulene-2-sulfo nylamino)-butyramide; (S) 4-Phenyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-butyric acid; (S) N-Hydroxy-4-phenyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-buty ramide; (S) 3-Methyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-butyric acid; (S) N-Hydroxy-3-methyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-buty ramide; (R) 2-(2,3-Dihydro-1H-8-oxa-cyclopenta[a] indene-6-sulfonylamino)-3-methyl-butyric acid; (R) 3-Methyl-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulene-2-sulfonylamino)- butyric acid; (R) 2-(2,3-Dihydro-1H-8-oxa-cyclopenta[a]indene-6-sulfonylamino)-N-hydroxy-3-m ethyl-butyramide; (R) N-Hydroxy-3-methyl-2-(6,7,8,9-tetrahydro-5H-10-oxa-benzo[a]azulene-2-sulfo nylamino)-butyramide; (R) 4-Phenyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-butyric acid; (R) N-Hydroxy-4-phenyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-buty ramide; (R) 3-Methyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-butyric acid; and (R) N-Hydroxy-3-methyl-2-(6,7,8,9-tetrahydro-5H-fluorene-2-sulfonylamino)-buty ramide; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof. 8. A method of inhibiting a matrix metalloproteinase comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 9. A method of inhibiting gelatinase A comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 10. A method of inhibiting stromelysin-1 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 11. A method of inhibiting collagenase-3 comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 12. A method of preventing atherosclerotic plaque rupture comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 13. A method of inhibiting aortic aneurysm comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 14. A method of inhibiting heart failure comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 15. A method of preventing restenosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 16. A method of controlling periodontal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 17. A method of treating comeal ulceration comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 18.A method of treating bums comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 19. A method of treating decubital ulcers comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 20. A method of treatment for healing wounds comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 21. A method of treating cancer comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 22. A method of treating arthritis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 23. A method of treating osteoporosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 24. A method of treating autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 25. A method of treating multiple sclerosis comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 26. A method of treating inflammation and pain comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 27. A method of treating acute and chronic neurodegenerative disorders selected from the group consisting of: stroke, head trauma, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral amyloid angiopathy, AIDS, Parkinson's disease, Huntington's diseases, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 28. A method of treating renal disease comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 29. A method of treating left ventricular dilation comprising administering to a host suffering therefrom a therapeutically effective amount of a compound according to claim 1 in unit dosage form. 30. A pharmaceutical composition comprising a compound according to claim 1 in admixture with a pharmaceutically acceptable excipient, diluent, or carrier. 31. A method for preparing a compound of Formula Ie ##STR42## wherein n is zero or an integer of 1 or 2; X is ##STR43## a side chain of a natural amino acid or a side chain of an unnatural amino acid; and corresponding isomers thereof; or a pharmaceutically acceptable salt thereof which comprises treating a compound of formula (15) ##STR44## wherein Ph is phenyl and n, X, and R.sup.1 are as defined above with a base in a solvent to give a compound of Formula Ie and if desired, converting a compound of compound of Formula Ie to a corresponding pharmaceutically acceptable salt by conventional means and, if so desired, converting the corresponding pharmaceutically acceptable salt to a compound of Formula Ie by conventional means.

Details for Patent 6,492,422

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2018-07-30